These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16142750)

  • 1. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
    Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2004 Jun; 31(6):1112-20. PubMed ID: 15170923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
    Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.
    Hara T; Ogawa F; Yanaba K; Iwata Y; Muroi E; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2009 Jan; 36(1):99-105. PubMed ID: 19208531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
    Hamaguchi Y; Fujimoto M; Matsushita T; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased serum soluble CD40 levels in patients with systemic sclerosis.
    Komura K; Fujimoto M; Matsushita T; Yanaba K; Kodera M; Kawasuji A; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2007 Feb; 34(2):353-8. PubMed ID: 17295440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis.
    Hasegawa M; Fujimoto M; Hamaguchi Y; Matsushita T; Inoue K; Sato S; Takehara K
    J Rheumatol; 2011 May; 38(5):877-84. PubMed ID: 21239758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of serum KL-6 and SP-D for the diagnosis and treatment of interstitial lung disease in patients with diffuse connective tissue disorders].
    Ogawa N; Shimoyama K; Kawabata H; Masaki Y; Wano Y; Sugai S
    Ryumachi; 2003 Feb; 43(1):19-28. PubMed ID: 12692986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis.
    Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Usui A; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 Aug; 36(8):1657-62. PubMed ID: 19531747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.
    Ogawa F; Shimizu K; Muroi E; Hara T; Hasegawa M; Takehara K; Sato S
    Rheumatology (Oxford); 2006 Jul; 45(7):815-8. PubMed ID: 16449367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
    Yanaba K; Komura K; Kodera M; Matsushita T; Hasegawa M; Takehara K; Sato S
    Ann Rheum Dis; 2006 Jan; 65(1):124-6. PubMed ID: 16344498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody.
    Komura K; Yanaba K; Ogawa F; Shimizu K; Takehara K; Sato S
    Clin Exp Dermatol; 2008 May; 33(3):329-32. PubMed ID: 18312458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased serum soluble OX40 in patients with systemic sclerosis.
    Komura K; Yoshizaki A; Kodera M; Iwata Y; Ogawa F; Shimizu K; Wayaku T; Yukami T; Murata M; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2008 Dec; 35(12):2359-62. PubMed ID: 18843780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical study on KL-6 and SP-D in sera of patients with various pulmonary diseases].
    Sugimoto H; Okada E; Hashimoto N; Suzuki S; Yoshida H; Totani Y; Ameshima S; Ishizaki T; Miyamori I
    Rinsho Byori; 2000 Jun; 48(6):554-60. PubMed ID: 10897675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Matsushita T; Yanaba K; Kodera M; Komura K; Takehara K; Sato S
    Rheumatology (Oxford); 2005 Jul; 44(7):873-8. PubMed ID: 15797972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.